Google Chrome
Safari
Firefox
Edge
Article / Sep 10, 2019
Inhalation Drug Delivery: The Impact of Particle Size Reduction
Pharmaceutical Technology, September 2, 2019
Search
Press Clipping / Sep 13, 2019
Kiel University and Hovione to develop high-dose inhalation formulations
in-PharmaTechnologist, September 3, 2019
Article / Apr 12, 2019
Developing and Characterizing DPI Formulations for Biologics
Pharma's Almanac, April 12, 2019
Press Release / Sep 20, 2019
Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
News / Sep 23, 2019
Hovione is a Best For The World 2019 Honoree
The Best For The World lists are determined based on the verified B Impact Assessments of Certified B Corporations
News / Sep 09, 2019
Hovione Cork achieves the Business Responsibly Mark Certification
The mark of a great company
News / Oct 08, 2019
Celebrating our 60th Anniversary in Cork
10 years in Cork, 60 years in the world.
Devices
Hovione offers simple, patented and globally competitive dry powder inhalers – Disposable, Capsule, Blister and Large Dose DPIs – which are available for fully integrated turn-key development with formulation and for licensing.